Stockhouse.com: Taking it to the street
Boards & Blogs
Active Resource Stocks
Natural Resources Bulletins
Natural Resources Wire
US Press Releases
Canadian Press Releases
Showcase News Releases
Tools & Resources
Jobs / Careers
Blogs at a Glance
My Favorite Blogs
CEO Interview & Company Overview
Northern Vertex | V.NEE
Other Recent Video
CEO Interview and Company Overview
Sniper Resources Ltd. | V.SIP
Breaking News: Kootenay Closes $8,253,850 Private Placement Financing
Kootenay Silver Inc. | V.KTN
Visit the Video Showcase
MissionIR Small-Cap Blog
add to favorites
Keryx Biopharmaceuticals, Inc. (KERX) Begins Phase II Study of Zerenex for Treatment of...
posted on 11/1/2012 6:12:50 PM | 361 reads | Post #155186
overall quality :
Average quality rating by the Stockhouse community.
Keryx Biopharmaceuticals, Inc. (KERX) Begins Phase II Study of Zerenex for Treatment of Patients with Kidney Disease
Keryx Biopharmaceuticals is focused on medically important pharmaceutical products for the treatment of renal disease. The company is currently developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes.
The company today announced the initiation of a Phase 2 study of Zerenex in managing serum phosphorus and iron deficiency in anemic patients with Stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD). In the U.S. alone, over 1.5 million people suffering from Stages 3-5 NDD-CKD have iron deficiency anemia. However, there are currently no oral iron supplements with an FDA label nor are there any FDA-approved phosphate binders.
The Phase 2 study started today is a multi-center, randomized, safety and efficacy clinical trial designed to compare the ability of Zerenex to manage serum phosphorus and iron deficiency versus placebo in anemic patients with Stages 3 to 5 NDD-CKD. The study plans to randomize about 150 patients in approximately 15 sites in the U.S.
Eligible patients will be randomized 1:1 to receive either Zerenex or placebo for a 12-week treatment period. The primary endpoints of the study are to demonstrate changes in ferritin, TSAT, and serum phosphorus levels over the 12-week treatment period. Secondary endpoints of the study include changes in hemoglobin and FGF-23. Study completion is expected sometime in mid-2013.
Zerenex is also in a long-term Phase 3 study, under Special Protocol Assessment, as a treatment for end-stage renal disease patients with hyperphosphatemia on dialysis. Top-line data from this study is expected to be announced around year-end. The NDA filing is expected to occur in the first quarter of 2013 for this indication.
For further information about Keryx Biopharmaceuticals and its Zerenex product, please visit
Please see disclaimer on the MissionIR website
add to favorites
login to comment
Featured News Links
Empire Industries announces Private Placement and creation of a 51% controlled Chinese JV
Top three reasons why you need to invest in this company
Game changer for Pangolin Diamonds, as explorer becomes discoverer of first kimberlite in Botswana
Kootenay drill program closes in on 100+ M Silver Eqv Milestone!
Register for the Vancouver Resource Investment Conference – May 26-27, 2013
Pacific North West Capital Corp.
Pacific North West Capital Corp. (TSX: PFN; OTCQX: PAWEF; Frankfurt: P7J)
is a mineral exploration company focused on the discovery, exploration and development of PGM and nickel-copper sulphide deposits in geologically prospective regions in North America, particularly Canada. The Company's key asset is its 100% owned River Valley PGM Project in the Sudbury region of northern Ontario. The River Valley Project is one of North America's most advanced primary PGM deposits...
Stockhouse.com is owned by
Stockhouse Publishing Ltd.
Financial Market Data powered by
All rights reserved. View the
NYSE/AMEX/NASDAQ and other data delayed 15 minutes unless otherwise indicated.
© 2013 Stockhouse publishing Ltd. All rights reserved. |